Our previous work demonstrated that neutralizing HMGB1 with a monoclonal antibody (mAb) significantly reduced brain infarction [15], hemorrhage [16], and traumatic brain injury [17] in rat models, primarily by protecting the blood–brain barrier (BBB) and inhibiting the inflammatory cascade [18]. This evidence concerns the gene HMGB1 and brain infarction.